Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East

6 days ago 5

TipRanks

Tue, January 6, 2026 astatine 7:37 AM CST 1 min read

LENZ Therapeutics (LENZ) announced an exclusive organisation statement for Lunatus to registry and commercialize VIZZ for the attraction of presbyopia successful the Middle East Region. LENZ Therapeutics is simply a pharmaceutical institution focused connected the commercialization of VIZZ 1.44%, the archetypal and lone FDA-approved aceclidine-based oculus driblet for the attraction of presbyopia. Lunatus is an autarkic pharmaceutical institution specialized successful the commercialization of pharmaceutical products successful the Middle East. Under the presumption of the agreement, LENZ volition person upfront, regulatory and commercialized milestone payments, successful summation to a important stock of gross generated successful the portion done a pre-determined minimum merchandise proviso price. Lunatus volition clasp exclusive commercialization rights for VIZZ for the attraction of presbyopia successful the Middle East region, including United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq. “As the commercialized motorboat of VIZZ successful the United States continues to physique momentum, we are pleased to grow our web of commercialized partnerships successful cardinal strategical regions extracurricular the United States. Lunatus represents our 4th commercialization concern for VIZZ, arsenic we stay profoundly committed to expanding planetary entree to this transformative presbyopia therapy,” said Eef Schimmelpennink, President and CEO of LENZ Therapeutics.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected LENZ:

Disclaimer & DisclosureReport an Issue

Overreaction to LENZ Therapeutics’ Stock Decline Presents Buying Opportunity Despite Isolated Retinal Tear Incident
Lenz Therapeutics selloff Friday an overreaction, says H.C. Wainwright
LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event
Lenz Therapeutics confirms caller adverse lawsuit submitted to FDA
LENZ Therapeutics Responds to FDA Adverse Event Report

Read Entire Article